I-MAK’s team has spent the last decade increasing transparency on patents, innovation, and access.
Biologics, Biosimilars and Patents: A Beginner’s Guide
Given the recent history of the BPCIA and the ongoing understanding of how the regulatory aspects are working in practice, including the multiple types of biologic products that are covered by the law, it can seem quite a complicated system for those not in the business. It is with this in mind that we created…
I-MAK & AELP: The Costs of Pharma Cheating
ITC Testimony
Request for Comments on USPTO Initiatives to Ensure the Robustness and Reliability of Patent Rights (USPTO Docket No. PTO-P-2022-0025)
Public Comment Joint USPTO-FDA Collaboration Initiatives; Notice of Public Listening Session
Supplemental Comments on the Joint USPTO-FDA Collaboration Initiatives Listening Session
Drug Patent Book
Overpatented, Overpriced 2022
The Truth About America’s Top Selling Drugs 2021
Letter to Senator Tillis
Partner with us now to build
a more just and equitable
medicine system for all.